Indomethacine Per Se Or Ester Thereof Patents (Class 514/420)
  • Patent number: 9918992
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: March 20, 2018
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Patent number: 9526925
    Abstract: The present disclosure provides a composition that maintains a high and desirable viscosity while having a high amount of alcohol. Suitable thickeners and gelling agents are mixed with the alcohol to achieve this effect. An emulsion stabilizer can also be added. These components can also be combined with a sunscreen. The resulting composition provides benefits such as cooling and desirable skin feel, but is still easily spreadable and viscous enough to function effectively as a sunscreen.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: December 27, 2016
    Assignee: Edgewell Personal Care Brands, LLC
    Inventors: Hui-Ing Donna Hwang, Grace Riccardi, Christine M. Popoff
  • Patent number: 9346803
    Abstract: Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: May 24, 2016
    Assignees: Vanderbilt University, The Trustees of the University of Pennsylvania
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • Patent number: 9216150
    Abstract: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: December 22, 2015
    Assignee: PLx Pharma Inc.
    Inventors: Upendra K. Marathi, Susann Edler Childress, Shaun L. Gammill, Robert W. Strozier
  • Publication number: 20150147281
    Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.
    Type: Application
    Filed: November 17, 2014
    Publication date: May 28, 2015
    Inventors: Patricia A. Denny, Paul C. Denny, Mahvash Navazesh
  • Publication number: 20150141350
    Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.
    Type: Application
    Filed: September 4, 2014
    Publication date: May 21, 2015
    Inventors: Rangaramanujam M. Kannan, Sujatha Kannan, Roberto Romero, Raghavendra S. Navath, Hui Dai, Anupa R. Menjoge
  • Publication number: 20150132385
    Abstract: The present invention relates to nanocrystalline solid dispersion compositions having discrete particles, wherein each discrete particle comprises crystals of at least one pharmaceutical active; veterinary active; nutraceutical active dispersed in the matrix of at least one crystallization inducer and/or coexisting with crystals of crystallization inducer, optionally along with pharmaceutically acceptable excipients. The present invention also encompasses a novel one-step process for generation of nanocrystalline solid dispersions. The present invention is particularly of use for improving the dissolution of pharmaceutical actives, veterinary actives; nutraceutical actives exhibiting dissolution-limited bioavailability. Dissolution enhancement is because of the decreased crystallite size of the pharmaceutical active.
    Type: Application
    Filed: March 7, 2013
    Publication date: May 14, 2015
    Inventors: Arvind Kumar Bansal, Ajay Kumar Raju Dantuluri, Shete Ganesh Bhaskarao, Pawar Yogesh Bapurao
  • Publication number: 20150133455
    Abstract: The invention relates to a cellprotective, neuroprotective and retinoprotective composition. In an embodiment of the invention, said composition comprises (i) Ramipril or Ramiprilate and (ii) folic acid. The composition of the invention can be used, in particular, for the prevention of loss of vision, or even for improving visual acuity and visual field in normal subjects, as well as for treating ophthalmologic pathologies, in particular: glaucoma, diabetic retinopathy, age related macular degeneration, hereditary dystrophy of the retina, uveitis, ammetropia (myopia, presbyopia). This combination of active principles could also be used in general conditions for treating general pathologies (cancer . . . ).
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventor: Raouf REKIK
  • Publication number: 20150126573
    Abstract: The present invention relates to methods and compositions for the prevention or treatment of chronic obstructive pulmonary disease.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 7, 2015
    Inventors: Jorge Bernardo Boczkowski, Serge Adnot, Maylis Dagouassat, Jean-Marie Gagliolo
  • Publication number: 20150093338
    Abstract: There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 2, 2015
    Inventor: Michael Farber
  • Patent number: 8992982
    Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: March 31, 2015
    Assignee: Iceutica Pty Ltd.
    Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch
  • Publication number: 20150065431
    Abstract: The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and/or an inhibitor of the Nax/SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1?, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Inventors: Wei Xu, Seok Jong Hong, Robert D. Galiano, Thomas A. Mustoe
  • Publication number: 20150045396
    Abstract: The present invention provides a prophylactic or therapeutic agent for giant cell tumors occurring in a bone and soft tissue or for chondrosarcoma, which comprises a non-steroidal anti-inflammatory agent or thiazolidine derivative as an active ingredient, and the like
    Type: Application
    Filed: March 18, 2013
    Publication date: February 12, 2015
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Akihiko Takeuchi, Hiroyuki Tsuchiya
  • Publication number: 20150030549
    Abstract: Topical compositions are disclosed that are useful for delivering a therapeutic level of an NSAID to a target within a subject having a local inflammatory disorder. A composition of the present invention comprises a Drug and a solvent system, wherein the solvent system comprises at least two solvent alcohols and wherein the solvent system is present in an amount sufficient to solubilize the Drug, the solvent system is a low alkanol system, and the composition is a single phase composition. Exemplary solvent systems are those for which one of the at least two solvent alcohols is polyethylene glycol, glycerin, butylene glycol, dipropylene glycol, propylene glycol, ethanol, isopropanol, or a derivative thereof. Optionally the local inflammatory disorder is pseudofolliculitis barbae, dermatitis, psoriasis, wounds, or sunburn.
    Type: Application
    Filed: August 11, 2014
    Publication date: January 29, 2015
    Inventors: Monique Renata Green, Kenton Fedde
  • Publication number: 20150010599
    Abstract: Methods and compositions for reducing bladder spasms are disclosed. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of acetaminophen and an effective amount of at least one non-steroidal anti-inflammatory agent (NSAID). In another embodiment, a method for reducing bladder spasms comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of at least one prostaglandin (PG) pathway inhibitor, wherein the at least one PG pathway inhibitor is not acetaminophen or an NSAID.
    Type: Application
    Filed: September 24, 2014
    Publication date: January 8, 2015
    Inventor: David A. DILL
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Publication number: 20140377214
    Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-infiammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 25, 2014
    Inventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
  • Publication number: 20140371261
    Abstract: Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Application
    Filed: October 17, 2012
    Publication date: December 18, 2014
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, VANDERBILT UNIVERSITY
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • Publication number: 20140363498
    Abstract: Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 11, 2014
    Inventors: Amarpreet S. Sawhney, William H. Ransone, II
  • Publication number: 20140328917
    Abstract: An organic compound nano-powder comprising a granular organic compound with an average particle diameter of 500 nm or less and a 90%-diameter of less than 1500 nm and a carbohydrate compound comprising at least any one of a sugar and a sugar alcohol and with amount of 0.3 times or more by mass relative to amount of the organic compound, a method for producing the same, and a suspension having the organic compound dispersed in a liquid dispersion medium in which the organic compound is insoluble or poorly soluble.
    Type: Application
    Filed: May 11, 2013
    Publication date: November 6, 2014
    Inventors: Takahiro Tada, Kazuhiro Kagami, Shiro Yokota
  • Publication number: 20140322327
    Abstract: A drug delivery system for sustained delivery of bioactive agents, the system includes a matrix including nanofibrillated cellulose derived from plant based material and at least one bioactive agent, and at least one support selected from synthetic polymers, bio compounds and natural polymers. Also, methods for the manufacture of the system and methods of using it.
    Type: Application
    Filed: November 15, 2012
    Publication date: October 30, 2014
    Applicant: UPM-KYMMENE CORPORATION
    Inventors: Antti Laukkanen, Ruzica Kolakovic, Leena Peltonen, Timo Laaksonen, Jouni Hirvonen, Heikki Lyytikainen, Harri Jukarainen, Prijo Kortesuo
  • Publication number: 20140256781
    Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Applicant: ICEUTICA PTY LTD.
    Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch
  • Publication number: 20140255494
    Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
    Type: Application
    Filed: May 22, 2014
    Publication date: September 11, 2014
    Applicant: ICEUTICA PTY LTD.
    Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch
  • Publication number: 20140255466
    Abstract: The present invention relates to a composition for enhancing transdermal absorption of a drug, containing a polyvalent alcohol having 3 to 8 carbon atoms, an organic acid having 2 to 20 carbon atoms, and a higher alcohol having 12 to 20 carbon atoms, and a patch preparation containing a support and a drug-containing adhesive layer containing the composition on one surface of the support.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 11, 2014
    Applicant: Nitto Denko Corporation
    Inventors: Tsuyoshi MUKOBATA, Arimichi OKAZAKI, Akinori HANATANI, Sachiko SAKAMOTO
  • Patent number: 8808751
    Abstract: A method for producing a composition comprising nanoparticles of a biologically active compound, comprising the step of: dry milling a solid biologically active compound and a millable grinding compound in a mill comprising a plurality of milling bodies, for a time period sufficient to produce a solid dispersion comprising nanoparticles of the biologically active compound dispersed in an at least partially milled grinding compound is described as are various compositions produced using such methods.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: August 19, 2014
    Assignee: Iceutica Pty Ltd.
    Inventors: Raffaele Cammarano, Felix Meiser, Almar Postma, Frank Caruso
  • Publication number: 20140206717
    Abstract: The present invention relates to methods for processing pharmaceutically active substances having poor water solubility in the presence of an inorganic matrix, e.g., magnesium aluminometasilicate, and a secondary polymer as a means of converting the crystalline API to substantially amorphous and stable form, i.e., the crystallinity is less than 5%. The methods of the invention result in more complete amorphization, increased solubility, drug loading and stability as compared to typical amorphization or literature methods.
    Type: Application
    Filed: August 10, 2012
    Publication date: July 24, 2014
    Inventors: John Higgins, David C. Dubost
  • Publication number: 20140199232
    Abstract: Disclosure of methods and compositions related to chemical conjugations to nanoparticles of polysaccharides cross-linked to poloxamers as well as nano-sized colloids comprised of polysaccharides and poloxamers. The nanoparticles may be produced by various methods including inverse miniemulsion polymerization processes which create nanogels of desired size, shape, and stability for controlled therapeutic drug delivery, imaging, and theragnostic applications.
    Type: Application
    Filed: July 16, 2013
    Publication date: July 17, 2014
    Applicant: NANODERM SCIENCES, INC.
    Inventors: Richard A. Winchurch, Roy R. Yeoman
  • Patent number: 8778400
    Abstract: A formulation for the delivery of an anti-inflammatory agent to a subject is described. In one particular application of the invention, the formulation comprises oil-based or aqueous droplets comprising indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetic acid) or celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl) pyrazol-1-yl]benzenesulfonamide) stabilized by nanoparticles, particularly silica nanoparticles.
    Type: Grant
    Filed: April 20, 2009
    Date of Patent: July 15, 2014
    Assignee: University of South Australia
    Inventors: Clive Allan Prestidge, Spomenka Simovic
  • Publication number: 20140194487
    Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
    Type: Application
    Filed: January 6, 2014
    Publication date: July 10, 2014
    Applicant: ICEUTICA PTY LTD.
    Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch
  • Publication number: 20140187481
    Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.
    Type: Application
    Filed: July 3, 2013
    Publication date: July 3, 2014
    Inventors: Arthur Tudor Tucker, Nigel Benjamin
  • Publication number: 20140170112
    Abstract: In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid-derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation.
    Type: Application
    Filed: March 8, 2012
    Publication date: June 19, 2014
    Applicant: VICUS THERAPEUTICS, LLC
    Inventors: John Maki, Newell Bascomb, Timothy J. Turner, Fredric Young
  • Publication number: 20140154320
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.
    Type: Application
    Filed: February 4, 2014
    Publication date: June 5, 2014
    Applicant: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. DILL
  • Publication number: 20140148438
    Abstract: There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 29, 2014
    Inventor: Michael Farber
  • Patent number: 8734847
    Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: May 27, 2014
    Assignee: Iceutica Py Ltd.
    Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H William Bosch
  • Publication number: 20140107085
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Application
    Filed: October 10, 2013
    Publication date: April 17, 2014
    Applicant: The Trustees of The University of Pennsylvania
    Inventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter
  • Publication number: 20140094439
    Abstract: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.
    Type: Application
    Filed: June 3, 2013
    Publication date: April 3, 2014
    Inventors: Upendra K. Marathi, Susann Edler Childress, Shaun L. Gammill, Robert W. Strozier
  • Patent number: 8685453
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.
    Type: Grant
    Filed: March 20, 2013
    Date of Patent: April 1, 2014
    Assignee: Wellesley Pharmaceuticals, LLC
    Inventor: David A. Dill
  • Patent number: 8673960
    Abstract: The present invention provides an indomethacin-containing external liquid preparation which provides good feeling of use, which exhibits high percutaneous absorption of indomethacin, and which, particularly in a low-temperature environment, does not cause precipitation of crystals with time. The present invention is drawn to an external liquid preparation containing indomethacin, a lower alcohol, water, a sulfite, and polyethylene glycol having an average molecular weight of 3,000 to 15,000.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: March 18, 2014
    Assignee: Kowa Co., Ltd.
    Inventors: Hiroshi Miura, Makoto Kanebako
  • Publication number: 20140050795
    Abstract: The present disclosure relates generally to binder powders for use in powder material processing and processes for their preparation. The disclosure further relates to binder powders for use in making solid powder compact forms, solid powder compact forms containing said binder powders and methods for making solid powder compact forms.
    Type: Application
    Filed: February 28, 2012
    Publication date: February 20, 2014
    Applicant: Monash University
    Inventors: David Morton, Laurence Orlando, Tony Q. Zhou, Louise C. Ho
  • Publication number: 20140038931
    Abstract: The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.
    Type: Application
    Filed: August 27, 2013
    Publication date: February 6, 2014
    Applicant: ACTIVUS PHARMA CO., LTD.
    Inventors: Takashi HIROKAWA, Takahiro TADA, Jun NIHIRA
  • Publication number: 20140023692
    Abstract: The invention provides an inflammation-responsive implantable device for the in situ delivery of one or more pharmaceutically active agents to a human or animal. The device comprises two differential release bioresponsive polymeric matrices (BPMs): an outer polymetric matrix and an inner polymeric matrix, both of which contain at least one pharmaceutically active agent or drug, typically an antibiotic and an anti-inflammatory agent, respectively. The therapeutically effective agent may be embedded in nanoparticles or nanobubbles. In response to inflammation, the pharmaceutically active agents are released, but at different rates: the rate of drug release from the inner polymeric matrix is lower than the rate of drug release from the outer polymeric matrix. Suitable polymers for forming the outer and inner polymeric matrices are hyaluronic acid and chitosan, respectively. A method of making the device and a method of treatment are also described.
    Type: Application
    Filed: November 28, 2011
    Publication date: January 23, 2014
    Inventors: Lisa Claire Du Toit, Viness Pillay, Yahya Essop Choonara, Thirumala Govender, Trevor Robin Carmichael
  • Publication number: 20140005151
    Abstract: Administering water-soluble or dispersible synthetic analogs or derivatives of astaxanthin, lutein, zeaxanthin, or lycophyll and/or other carotenoids to a subject may reduce some of the adverse effects of inflammation in a body organ or tissue. The analogs or derivatives may be incorporated into pharmaceutical, over-the-counter, or nutraceutical preparations. Administration of the analogs or derivatives described herein may reduce deposition of inflammatory mediators such as C-reactive protein, complement system proteins or the membrane attack complex (MAC) in tissues. Reduced deposition of these molecules in tissues may reduce cell damage and/or lysis in the tissues.
    Type: Application
    Filed: June 19, 2013
    Publication date: January 2, 2014
    Inventor: Samuel F. Lockwood
  • Publication number: 20130344066
    Abstract: There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions. Identified biomarkers can be used to determine the disease state for a subject with an autoimmune disease or other condition.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 26, 2013
    Applicant: Sequenta, Inc.
    Inventors: Malek Faham, Thomas Willis
  • Publication number: 20130344159
    Abstract: The present invention relates to a polymer obtained from the polymerization of: (i) at least one monomer of formula (I) (CH2?CR1)CO—K (1) wherein: K represents O—Z or NH—Z, Z representing (CR2R3)m-CH3, (CH2—CH2—O)m-H, (CH2—CH2—O)m-CH3, (CH2)m-NR4R5 with m representing an integer from 1 to 30; R1, R2, R3, R4 and R5 independently represent H or a C1-C6 alkyl; (ii) at least between 0.1 and 50% mol, advantageously between 1 and 30% mol, more advantageously between 1 and 20 mol % of a cyclic monomer having a exomethylene group of formula (II) wherein: R6, R7, R8 and R9 represent independently H or a C5-C7 aryl group or R6 and R9 are absent and R7 and R8 form together with the carbon atom on which they are bonded a C5-C7 aryl group; i and j represent independently an integer chosen between 0 and 2; X represents either O or X is not present and in this latter case, CR6R7 and CR8R9 are linked via a single bond C—C and (iii) at least one bio-resorbable block copolymer cross-linker.
    Type: Application
    Filed: March 9, 2012
    Publication date: December 26, 2013
    Applicants: OCCLUGEL, UNIVERSITE PARIS DIDEROT - PARIS 7, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Laurence Moine, Alexandre Laurent, Michel Wassef, Laurent Bedouet, Stephanie Louguet, Valentin Verret, Emeline Servais
  • Publication number: 20130337031
    Abstract: The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.
    Type: Application
    Filed: March 8, 2013
    Publication date: December 19, 2013
    Applicant: Nuvo Research Inc.
    Inventor: Nuvo Research Inc.
  • Publication number: 20130338569
    Abstract: A polymeric hydrogel composition is described for the delivery of a pharmaceutically active agent when an electrical stimulus is applied to the composition. The composition comprises a polymer which forms the hydrogel, such as poly vinyl alcohol (PVA) cross-linked with diethyl acetamidomalonate (DAA), an electroactive polymer such as polyaniline and a pharmaceutically active agent such as an analgesic, and in particular, indomethacin. The composition can be subcutaneously implanted at a targeted site and under normal conditions, the active agent will be entrapped in the hydrogel itself. However, upon the application of an electric current to the hydrogel, the active agent will be released. When the electric current is removed, the change is reversed and the active agent will cease to be released. In one embodiment of the invention, the hydrogel composition is for use in alleviating chronic pain.
    Type: Application
    Filed: November 28, 2011
    Publication date: December 19, 2013
    Applicant: UNIVERSITY OF WITWATERSRAND, JOHANNESBURG
    Inventors: Thomas Tsai, Viness Pillay, Yahya Essop Choonara, Lisa Claire Du Toit
  • Publication number: 20130337077
    Abstract: Provided is a nanosphere for delivery of a therapeutic agent comprising: a polymer matrix; discrete liquid oil droplets dispersed in the polymer matrix; and a therapeutic agent dissolved or dispersed in the oil. In some embodiments, the nanosphere is pegylated. In some embodiments, the nanosphere has a diameter of from about 100 nm to about 300 nm. In further preferred embodiments, the nanosphere has a diameter of from about 150 nm to about 250 nm. In yet further embodiments, the nanosphere has a diameter of from about 180 nm to about 220 nm. In some embodiments, the oil comprises a lipid or a phospholipid. In further embodiments, the lipid or the phospholipid has a melting point below 20° C. In some embodiments, the polymer is a natural, modified or synthetic polymer. In further embodiments, the polymer is biodegradable.
    Type: Application
    Filed: June 14, 2013
    Publication date: December 19, 2013
    Inventors: Ho Lun Wong, Mayuri Narvekar, Hui Yi Xue
  • Publication number: 20130338121
    Abstract: The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.
    Type: Application
    Filed: February 28, 2012
    Publication date: December 19, 2013
    Inventors: Le Tien Canh, Mircea-Alexandru Mateescu
  • Publication number: 20130324503
    Abstract: The present invention relates to methods of treatment for Parkinson Disease (PD) in a person by identifying gene variants which may indicate a more favorable response to specific medicaments, thereby allowing for personalized or individualized treatment. The present invention relates to a method of screening for a genetic predisposition to PD in a person. The present invention is also directed to a method of testing a person for the presence of particular gene variants, wherein the presence of a gene variant indicates a higher predisposition to PD, and the absence of a gene variant indicates a lower predisposition to PD, compared to a control sample. The present invention further relates to methods and kits for treating, or inhibiting the development of, PD in a person. The present invention is also directed to a method of identifying the heritage of an individual based on the genetic profile of the individual.
    Type: Application
    Filed: October 19, 2012
    Publication date: December 5, 2013
    Applicants: Health Research Inc., Emory University School of Medicine, National Institute of Environmental Health Sciences, Veterans Affairs Puget Sound Health Care System, Oregon Health & Science University
    Inventors: Haydeh Payami, Taye H. Hamza, Stewart A. Factor, John Nutt, Cyrus Zabetian, Honglei Chen, Erin Hill Burns
  • Publication number: 20130323179
    Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
    Type: Application
    Filed: May 3, 2013
    Publication date: December 5, 2013
    Applicant: Johns Hopkins University, The
    Inventors: Alexey Popov, Elizabeth M. Enlow, James Bourassa, Colin R. Gardner, Hongming Chen, Laura M. Ensign, Samuel K. Lai, Tao Yu, Justin Hanes, Ming Yang